Dengue is the fastest spreading vector-borne viral disease, according to the World Health Organization, and is endemic in over 100 countries. Four in 10 people are at risk of getting infected.

More than two thirds of the world's dengue cases come from Asia, with Southeast Asia a major contributor.

Sanofi Pasteur said it aims to put its vaccine in markets where it is most needed first, including the Southeast Asia.

"The overall ambition is first to address the disease where it is most severe," said Leroy.

As soon as its vaccine is approved for use, Sanofi Pasteur will be able to churn out 100 million doses a year. Long before the vaccine neared completion, the company invested in a 350 million euro production plant located in France in 2009.